Psychedelic Medicine,
Journal Year:
2023,
Volume and Issue:
1(4), P. 241 - 252
Published: Aug. 30, 2023
N-methyl-D-aspartate
receptor-mediated
dissociatives
and
serotonergic
hallucinogens
are
being
increasingly
used
in
therapeutic
interventions
that
involve
nonordinary
states
of
consciousness
may
represent
a
unique
mental
health
paradigm
wherein
pharmacologically
induced
experiences
conducive
to
psychological
well-being.The
aim
this
study
was
further
understand
how
the
phenomenological
health-promoting
effects
high-dose
dextromethorphan
(DXM)
compared
psilocybin
same
participants
when
administered
under
experimental
conditions
typical
psychedelic
trials.Single,
acute
oral
doses
DXM
(400
mg/70
kg),
(10,
20,
30
inactive
placebo
were
double-blind
psychologically
supportive
20
healthy
with
histories
hallucinogen
use.
Ratings
personal
meaning,
spiritual
significance,
challenge,
insight
attributed
drug
assessed
7
h
(at
session
end)
1
week
after
each
administration.
Persisting
administration.High-dose
produced
similar
increases
over
ratings
experience
predictive
benefit
at
week,
even
expectancy
minimized.
These
tended
favor
dose-dependent
manner
limited
by
poor
physical
tolerability
for
DXM.This
analysis
suggests
utility
exploring
clinical
applications
occur
within
contexts
characteristic
research
prioritize
optimization
valuable
experiences.
This
registered
ClinicalTrials.gov
(NCT02033707).
International Review of Psychiatry,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 13
Published: Sept. 23, 2024
Dissociative
therapies
are
being
increasingly
explored
for
their
psychiatric
applications,
although
questions
remain
about
how
they
work
and
best
to
use
them.
In
exploring
these
questions,
this
review
highlights
six
key
areas
of
clinical
relevance:
(1)
The
possible
contributions
functional
unblinding
when
interpreting
efficacy
data;
(2)
degree
which
the
therapeutic
effects
dissociative
can
be
distinguished
from
transient
forms
relief
seen
with
recreational
drug
use;
(3)
Understanding
construct
dissociation
as
it
is
tasked
describing
function
drugs;
(4)
investigation
subjective
predictors
outcome;
(5)
Similarities
differences
in
classic
psychedelics;
(6)
anticipated
need
judicious
prescribing/deprescribing
resources
proliferate.
European Neuropsychopharmacology,
Journal Year:
2023,
Volume and Issue:
78, P. 54 - 63
Published: Nov. 4, 2023
Major
depressive
disorder
(MDD)
is
a
serious
disease
and
burden
to
patients,
families
society.
Rodent
experiments
human
studies
suggest
that
several
neuropeptide
systems
are
involved
in
mood
regulation.
The
aim
of
this
study
two-fold:
(i)
monitor,
with
qPCR,
transcript
levels
the
substance
P/tachykinin
(TAC),
NPY
CCK
bulk
samples
from
control
suicide
subjects,
targeting
five
postmortem
brain
regions
including
locus
coeruleus
(LC);
(ii)
analyse
expression
family
transcripts
LC
neurons
'normal'
brains
by
using
laser
capture
microdissection
Smart-Seq2
RNA
sequencing.
qPCR
revealed
distinct
regional
patterns
male
female
controls
higher
for
TAC
system
dorsal
raphe
nucleus
LC,
versus
prefrontal
cortex.
In
TAC,
receptors
few
were
increased
mainly
cortex
LC.
second
on
noradrenergic
GAL,
NPY,
TAC1,
CCK,
TACR1
many
other
peptides
(e.g.
Cerebellin4
CARTPT)
Adcyap1R1
GPR173).
These
data
our
previous
results
indicates
tachykinin
galanin
may
be
valid
targets
developing
antidepressant
medicines.
Moreover,
perturbation
MDD
detection
further
receptor
shed
new
light
signalling
mechanisms
possibly
associated
disorders.
Psychedelic Medicine,
Journal Year:
2023,
Volume and Issue:
1(4), P. 241 - 252
Published: Aug. 30, 2023
N-methyl-D-aspartate
receptor-mediated
dissociatives
and
serotonergic
hallucinogens
are
being
increasingly
used
in
therapeutic
interventions
that
involve
nonordinary
states
of
consciousness
may
represent
a
unique
mental
health
paradigm
wherein
pharmacologically
induced
experiences
conducive
to
psychological
well-being.The
aim
this
study
was
further
understand
how
the
phenomenological
health-promoting
effects
high-dose
dextromethorphan
(DXM)
compared
psilocybin
same
participants
when
administered
under
experimental
conditions
typical
psychedelic
trials.Single,
acute
oral
doses
DXM
(400
mg/70
kg),
(10,
20,
30
inactive
placebo
were
double-blind
psychologically
supportive
20
healthy
with
histories
hallucinogen
use.
Ratings
personal
meaning,
spiritual
significance,
challenge,
insight
attributed
drug
assessed
7
h
(at
session
end)
1
week
after
each
administration.
Persisting
administration.High-dose
produced
similar
increases
over
ratings
experience
predictive
benefit
at
week,
even
expectancy
minimized.
These
tended
favor
dose-dependent
manner
limited
by
poor
physical
tolerability
for
DXM.This
analysis
suggests
utility
exploring
clinical
applications
occur
within
contexts
characteristic
research
prioritize
optimization
valuable
experiences.
This
registered
ClinicalTrials.gov
(NCT02033707).
